Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 May;100(1):15–20. doi: 10.1111/j.1476-5381.1990.tb12044.x

Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes.

L Ménard 1, S Pilote 1, P H Naccache 1, M Laviolette 1, P Borgeat 1
PMCID: PMC1917464  PMID: 2164857

Abstract

1. We have investigated the inhibitory activity of compound MK-886 (formerly L-663,536), an indole derivative, on 5-lipoxygenase product synthesis in various human phagocytes stimulated with either the ionophore A23187, in the presence and absence of exogenous arachidonic acid, or platelet-activating factor (PAF). The lipoxygenase products were analysed by reversed-phase h.p.l.c. 2. MK-886 inhibited the formation of 5-hydroxy-eicosatetraenoic acid (5-HETE), leukotriene B4 (LTB4), its omega-oxidation products and 6-trans-isomers with an IC50 value of 10-14 nM in A23187-stimulated neutrophils. In the same system, nordihydroguaiaretic acid (NDGA), AA-861 and L-655,240 showed IC50 values of 250-510, 110-420 nM and 1.7-3.9 microM, respectively. 3. MK-886 inhibited 5-lipoxygenase product synthesis in A23187-stimulated blood eosinophils and monocytes, and in neutrophils primed with granulocyte-macrophage colony-stimulating factor and stimulated with PAF with IC50 values of 1-13 nM. 4. The inhibitory activity of MK-886 was not reversed by addition of 10 microM arachidonic acid to A23187-stimulated neutrophils. 5. Compound MK-886 had no effect on 15-lipoxygenase product synthesis in blood eosinophils and neutrophils up to a concentration of 1 microM. 6. At 100 nM compound MK-886 had no significant effects on calcium ion mobilization, superoxide anion production and actin polymerization in neutrophils. 7. In conclusion, MK-886 is a very potent and specific inhibitor of both LTB4 and LTC4 synthesis in various types of human phagocytes.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borgeat P., Nadeau M., Salari H., Poubelle P., Fruteau de Laclos B. Leukotrienes: biosynthesis, metabolism, and analysis. Adv Lipid Res. 1985;21:47–77. doi: 10.1016/b978-0-12-024921-3.50008-3. [DOI] [PubMed] [Google Scholar]
  2. Borgeat P., Picard S. 19-Hydroxyprostaglandin B2 as an internal standard for on-line extraction-high-performance liquid chromatography analysis of lipoxygenase products. Anal Biochem. 1988 Jun;171(2):283–289. doi: 10.1016/0003-2697(88)90487-3. [DOI] [PubMed] [Google Scholar]
  3. Borgeat P., Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3213–3217. doi: 10.1073/pnas.76.7.3213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bray M. A., Cunningham F. M., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol. 1981 Mar;72(3):483–486. doi: 10.1111/j.1476-5381.1981.tb11000.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  6. Faucher N., Naccache P. H. Relationship between pH, sodium, and shape changes in chemotactic-factor-stimulated human neutrophils. J Cell Physiol. 1987 Sep;132(3):483–491. doi: 10.1002/jcp.1041320310. [DOI] [PubMed] [Google Scholar]
  7. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  8. Frigas E., Gleich G. J. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986 Apr;77(4):527–537. doi: 10.1016/0091-6749(86)90341-6. [DOI] [PubMed] [Google Scholar]
  9. Gillard J., Ford-Hutchinson A. W., Chan C., Charleson S., Denis D., Foster A., Fortin R., Leger S., McFarlane C. S., Morton H. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989 May;67(5):456–464. doi: 10.1139/y89-073. [DOI] [PubMed] [Google Scholar]
  10. Goldyne M. E., Burrish G. F., Poubelle P., Borgeat P. Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenase-related pathways. J Biol Chem. 1984 Jul 25;259(14):8815–8819. [PubMed] [Google Scholar]
  11. Grynkiewicz G., Poenie M., Tsien R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985 Mar 25;260(6):3440–3450. [PubMed] [Google Scholar]
  12. Hall R. A., Gillard J., Guindon Y., Letts G., Champion E., Ethier D., Evans J., Ford-Hutchinson A. W., Fortin R., Jones T. R. Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist. Eur J Pharmacol. 1987 Mar 17;135(2):193–201. doi: 10.1016/0014-2999(87)90611-x. [DOI] [PubMed] [Google Scholar]
  13. Howard T. H., Oresajo C. O. A method for quantifying F-actin in chemotactic peptide activated neutrophils: study of the effect of tBOC peptide. Cell Motil. 1985;5(6):545–557. doi: 10.1002/cm.970050609. [DOI] [PubMed] [Google Scholar]
  14. Lambeth J. D. Activation of the respiratory burst oxidase in neutrophils: on the role of membrane-derived second messengers, Ca++, and protein kinase C. J Bioenerg Biomembr. 1988 Dec;20(6):709–733. doi: 10.1007/BF00762549. [DOI] [PubMed] [Google Scholar]
  15. Laviolette M., Coulombe R., Picard S., Braquet P., Borgeat P. Decreased leukotriene B4 synthesis in smokers' alveolar macrophages in vitro. J Clin Invest. 1986 Jan;77(1):54–60. doi: 10.1172/JCI112301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McColl S. R., Krump E., Naccache P. H., Borgeat P. Enhancement of human neutrophil leukotriene synthesis by human granulocyte-macrophage colony-stimulating factor. Agents Actions. 1989 Jun;27(3-4):465–468. doi: 10.1007/BF01972854. [DOI] [PubMed] [Google Scholar]
  17. Metcalf D., Begley C. G., Johnson G. R., Nicola N. A., Vadas M. A., Lopez A. F., Williamson D. J., Wong G. G., Clark S. C., Wang E. A. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1986 Jan;67(1):37–45. [PubMed] [Google Scholar]
  18. Mita H., Yui Y., Shida T. Effect of AA-861, a 5-lipoxygenase inhibitor, on leukotriene synthesis in human polymorphonuclear leukocytes and on cyclooxygenase and 12-lipoxygenase activities in human platelets. Allergy. 1986 Sep;41(7):493–498. doi: 10.1111/j.1398-9995.1986.tb00334.x. [DOI] [PubMed] [Google Scholar]
  19. Nadeau M., Fruteau de Laclos B., Picard S., Braquet P., Corey E. J., Borgeat P. Studies on leukotriene B4 omega-oxidation in human leukocytes. Can J Biochem Cell Biol. 1984 Dec;62(12):1321–1326. doi: 10.1139/o84-168. [DOI] [PubMed] [Google Scholar]
  20. Poubelle P. E., Borgeat P., Rola-Pleszczynski M. Assessment of leukotriene B4 synthesis in human lymphocytes by using high performance liquid chromatography and radioimmunoassay methods. J Immunol. 1987 Aug 15;139(4):1273–1277. [PubMed] [Google Scholar]
  21. Rossi F. The O2- -forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function. Biochim Biophys Acta. 1986 Nov 4;853(1):65–89. doi: 10.1016/0304-4173(86)90005-4. [DOI] [PubMed] [Google Scholar]
  22. Rouzer C. A., Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem. 1988 Aug 5;263(22):10980–10988. [PubMed] [Google Scholar]
  23. Salari H., Braquet P., Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med. 1984 Jan;13(1):53–60. doi: 10.1016/0262-1746(84)90102-1. [DOI] [PubMed] [Google Scholar]
  24. Samuelsson B., Dahlén S. E., Lindgren J. A., Rouzer C. A., Serhan C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171–1176. doi: 10.1126/science.2820055. [DOI] [PubMed] [Google Scholar]
  25. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  26. Sha'afi R. I., Molski T. F. Activation of the neutrophil. Prog Allergy. 1988;42:1–64. doi: 10.1159/000318681. [DOI] [PubMed] [Google Scholar]
  27. Shaw R. J., Cromwell O., Kay A. B. Preferential generation of leukotriene C4 by human eosinophils. Clin Exp Immunol. 1984 Jun;56(3):716–722. [PMC free article] [PubMed] [Google Scholar]
  28. Weller P. F., Lee C. W., Foster D. W., Corey E. J., Austen K. F., Lewis R. A. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7626–7630. doi: 10.1073/pnas.80.24.7626. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES